Although natriuretic peptides cannot replace cardiac MRI, they may serve as accessible, low-cost adjunct biomarkers for screening, monitoring, and early warning of myocardial iron overload, particularly where MRI is limited. Further prospective studies are warranted to validate their role in longitudinal assessment and risk prediction.
Kharaghani et al. (Sat,) studied this question.